Best Practice & Research Clinical Rheumatology, Journal Year: 2024, Volume and Issue: unknown, P. 102032 - 102032
Published: Dec. 1, 2024
Language: Английский
Best Practice & Research Clinical Rheumatology, Journal Year: 2024, Volume and Issue: unknown, P. 102032 - 102032
Published: Dec. 1, 2024
Language: Английский
Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15
Published: Oct. 25, 2024
Artemisinin and its derivatives are widely recognized as first-line treatments for malaria worldwide. Recent studies have demonstrated that artemisinin-based antimalarial drugs, such artesunate, dihydroartemisinin, artemether, not only possess excellent properties but also exhibit antitumor, antifungal, immunomodulatory effects. Researchers globally synthesized artemisinin like SM735, SM905, SM934, which offer advantages low toxicity, high bioavailability, potential immunosuppressive properties. These compounds induce immunosuppression by inhibiting the activation of pathogenic T cells, suppressing B cell antibody production, enhancing differentiation regulatory cells. This review summarized mechanisms analogs modulate excessive inflammation immune responses in rheumatic skeletal diseases, autoimmune inflammatory disorders, through pathways including TNF, Toll-like receptors, IL-6, RANKL, MAPK, PI3K/AKT/mTOR, JAK/STAT, NRF2/GPX4. Notably, context NF-κB pathway, inhibits expression disrupting upstream cascades and/or directly binding to downregulates multiple downstream genes controlled NF-κB, chemokines their receptors. targets regulate various functions, apoptosis, proliferation, signal transduction, antioxidant responses, ultimately intervening systemic diseases organs kidneys, nervous system, skin, liver, biliary system modulating dysregulation responses. Ongoing multicenter randomized clinical trials investigating effects these on rheumatic, inflammatory, with aim translating promising preclinical data into applications.
Language: Английский
Citations
2Seminars in Oncology Nursing, Journal Year: 2024, Volume and Issue: 40(5), P. 151718 - 151718
Published: Aug. 20, 2024
Evidence suggests that lower levels of morning energy are associated with higher stress and resilience in patients receiving chemotherapy. Study purposes were to identify subgroups distinct profiles; evaluate for differences among the profiles demographic clinical characteristics, as well measures stress, resilience, coping.
Language: Английский
Citations
0Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)
Published: Dec. 16, 2024
Language: Английский
Citations
0Best Practice & Research Clinical Rheumatology, Journal Year: 2024, Volume and Issue: unknown, P. 102032 - 102032
Published: Dec. 1, 2024
Language: Английский
Citations
0